Thane E. Underdahl

Array ( [id] => 15432225 [patent_doc_number] => 20200030295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => HETEROCYCLIC DIAMIDINES [patent_app_type] => utility [patent_app_number] => 16/322771 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7681 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16322771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049751 [patent_doc_number] => 20170326095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'PARENTERAL ESMOLOL FORMULATION' [patent_app_type] => utility [patent_app_number] => 15/663645 [patent_app_country] => US [patent_app_date] => 2017-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3710 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15663645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790447 [patent_doc_number] => 20180155318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => METHODS OF USE OF CYCLIC AMIDE DERIVATIVES TO TREAT SCHIZOPHRENIA [patent_app_type] => utility [patent_app_number] => 15/656062 [patent_app_country] => US [patent_app_date] => 2017-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15656062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14774787 [patent_doc_number] => 20190262291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => METHODS AND COMPOSITIONS FOR ALLEVIATING MYOPATHY [patent_app_type] => utility [patent_app_number] => 16/318023 [patent_app_country] => US [patent_app_date] => 2017-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -68 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318023 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15144827 [patent_doc_number] => 20190350891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => METHODS FOR TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS [patent_app_type] => utility [patent_app_number] => 16/317914 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13687325 [patent_doc_number] => 20170354617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => METHOD OF TREATING OR PREVENTING OSTEOPOROSIS [patent_app_type] => utility [patent_app_number] => 15/618783 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3347 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15618783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828415 [patent_doc_number] => 20200129489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA [patent_app_type] => utility [patent_app_number] => 16/617721 [patent_app_country] => US [patent_app_date] => 2017-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680959 [patent_doc_number] => 20180118819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => TREATMENT OF AGE-RELATED AND MITOCHONDRIAL DISEASES BY INHIBITION OF HIF-1 ALPHA FUNCTION [patent_app_type] => utility [patent_app_number] => 15/607346 [patent_app_country] => US [patent_app_date] => 2017-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15607346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956024 [patent_doc_number] => 20170260175 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE' [patent_app_type] => utility [patent_app_number] => 15/603145 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34220 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15603145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17306249 [patent_doc_number] => 11207331 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Agents, compositions and methods for enhancing neurological function [patent_app_type] => utility [patent_app_number] => 15/603267 [patent_app_country] => US [patent_app_date] => 2017-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 54 [patent_no_of_words] => 24156 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15603267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18084339 [patent_doc_number] => 11534446 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-27 [patent_title] => Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties [patent_app_type] => utility [patent_app_number] => 15/601214 [patent_app_country] => US [patent_app_date] => 2017-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 5870 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15601214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17679984 [patent_doc_number] => 11364214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Compositions and methods for treating eczema [patent_app_type] => utility [patent_app_number] => 16/302639 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8815 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16302639 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12962500 [patent_doc_number] => 09873682 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-23 [patent_title] => Apoptosis signal-regulating kinase inhibitor [patent_app_type] => utility [patent_app_number] => 15/491689 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10165 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15491689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11992351 [patent_doc_number] => 20170296506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-19 [patent_title] => 'METHODS FOR ADMINISTRATION AND METHODS FOR TREATING CARDIOVASCULAR DISEASES WITH RESINIFERATOXIN' [patent_app_type] => utility [patent_app_number] => 15/487263 [patent_app_country] => US [patent_app_date] => 2017-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 10013 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15487263 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11969744 [patent_doc_number] => 20170273898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'COMPOUNDED TOPICAL COMPOSITION AND METHOD' [patent_app_type] => utility [patent_app_number] => 15/484570 [patent_app_country] => US [patent_app_date] => 2017-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12971 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15484570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16009131 [patent_doc_number] => 20200179408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => INHIBITION OF CATALYTIC SITE COMMON TO MULTIPLE 3 ALPHA-OXIDOREDUCTASES FOR TREATMENT OF PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 16/088224 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16108275 [patent_doc_number] => 20200206160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => COMPOSITION AND METHODS OF TREATMENT [patent_app_type] => utility [patent_app_number] => 16/088372 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13827 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099027 [patent_doc_number] => 20190091189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => ADMINISTRATION OF EXOGENOUS KETONE TO LOWER BLOOD GLUCOSE [patent_app_type] => utility [patent_app_number] => 16/086748 [patent_app_country] => US [patent_app_date] => 2017-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16246030 [patent_doc_number] => 10745370 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Farnesyl transferase inhibitors and uses thereof [patent_app_type] => utility [patent_app_number] => 16/087103 [patent_app_country] => US [patent_app_date] => 2017-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9379 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16087103 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099057 [patent_doc_number] => 20190091204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => COMPOSITIONS OF DEFERASIROX [patent_app_type] => utility [patent_app_number] => 16/085714 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085714 [rel_patent_id] =>[rel_patent_doc_number] =>)